Compare AbCellera Biologics Inc (ABCL) vs Carnival Corp (CCL) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Carnival Corporation (CCL) trades at $26.68, down 4.41% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamental recovery with revenue growing to $26.62B in 2025 and net income reaching $2.76B. Positive analyst sentiment exists with a $35.45 consensus price target, though near-term headwinds in European demand and cost pressures are noted.

The outlook for CCL is cautiously optimistic. Strong booking trends and debt reduction support long-term growth, but investors face risks from geopolitical issues, fuel costs, and competitive pressures. The stock presents potential upside from current levels if execution continues, but requires monitoring of guidance and macroeconomic factors.